Prime Medicine, Inc.

NasdaqGM PRME

Prime Medicine, Inc. Receivables for the quarter ending September 30, 2024: USD 0.00

Prime Medicine, Inc. Receivables is USD 0.00 for the quarter ending September 30, 2024, a 0.00% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Prime Medicine, Inc. Receivables for the quarter ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Prime Medicine, Inc. Receivables for the quarter ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Prime Medicine, Inc. Receivables for the quarter ending September 30, 2021 was USD 0.00.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqGM: PRME

Prime Medicine, Inc.

CEO	Dr. Keith Michael Gottesdiener M.D., Ph.D.
IPO Date	Oct. 20, 2022
Location	United States
Headquarters	21 Erie Street
Employees	234
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years